Drugs & Targets Bayer’s Aliqopa gets FDA accelerated approval for relapsed follicular lymphoma September 15, 2017Vol.43 No.34
Drugs & Targets Cemiplimab receives FDA breakthrough designation for advanced cutaneous squamous cell carcinoma September 15, 2017Vol.43 No.34
Drugs & Targets EC approves Merck’s Keytruda for locally advanced, metastatic urothelial carcinoma September 08, 2017Vol.43 No.33
Drugs & Targets FDA grants orphan drug status to Cellect’s ApoGraft for acute and chronic GvHD September 08, 2017Vol.43 No.33
Drugs & Targets Gazyva in previously untreated follicular lymphoma gets FDA priority review September 01, 2017Vol.43 No.32
Drugs & Targets FDA approves inotuzumab ozogamicin for relapsed or refractory B-cell precursor ALL September 01, 2017Vol.43 No.32
Drugs & Targets Novartis’s Kymriah becomes first gene therapy to get FDA approval September 01, 2017Vol.43 No.32
Drugs & Targets FDA approves Mylotarg for treatment of acute myeloid leukemia September 01, 2017Vol.43 No.32
Drugs & Targets FDA approves Lynparza (olaparib) tablets for maintenance treatment in ovarian cancer September 01, 2017Vol.43 No.32
